Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF | Mon, 08/10/2026 - 07:00 — Investors

←Back to story

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF | Mon, 08/10/2026 - 07:00

InvestorsView source article

Part of story

Tenax’s TNX-103 fails primary endpoint in Phase 3 PH-HFpEF trial

Tenax Therapeutics' stock collapsed on August 10, 2026, after the company announced its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) failed to significantly improve walking distance in patients with pulmonary hypertension associated with heart failure compared to placebo, missing its primary endpoint.